The Department of Justice is investigating Semler Scientific (SMLR) for possible violations of a federal anti-fraud law related to its marketing of a product known as QuantaFlo, a test used in the diagnosis of peripheral artery disease by UnitedHealth Group (UNH) and other large insurers, STAT’s Lizzy Lawrence and Casey Ross report. Semler has recently disclosed that the government is investigating the use of QuantaFlo related to claims made for reimbursement from government health programs, which in some cases pay insurers more money to cover patients diagnosed with peripheral artery disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMLR:
- Semler Scientific’s Supplier Dependency Poses Financial Risks Amid Potential Disruptions
- Semler Scientific’s Earnings Call: Bitcoin Strategy Shines Amid Challenges
- Semler Scientific Reports Strong 2024 Earnings Driven by Bitcoin Strategy
- Semler Scientific reports Q4 EPS $3.41 vs. 55c last year
- SMLR Earnings this Week: How Will it Perform?